- WORLD EDITIONAustraliaNorth AmericaWorld
Investing News NetworkYour trusted source for investing success
- Lithium Outlook
- Oil and Gas Outlook
- Gold Outlook Report
- Uranium Outlook
- Rare Earths Outlook
- All Outlook Reports
- Top Generative AI Stocks
- Top EV Stocks
- Biggest AI Companies
- Biggest Blockchain Stocks
- Biggest Cryptocurrency-mining Stocks
- Biggest Cybersecurity Companies
- Biggest Robotics Companies
- Biggest Social Media Companies
- Biggest Technology ETFs
- Artificial Intellgience ETFs
- Robotics ETFs
- Canadian Cryptocurrency ETFs
- Artificial Intelligence Outlook
- EV Outlook
- Cleantech Outlook
- Crypto Outlook
- Tech Outlook
- All Market Outlook Reports
- Cannabis Weekly Round-Up
- Top Alzheimer's Treatment Stocks
- Top Biotech Stocks
- Top Plant-based Food Stocks
- Biggest Cannabis Stocks
- Biggest Pharma Stocks
- Longevity Stocks to Watch
- Psychedelics Stocks to Watch
- Top Cobalt Stocks
- Small Biotech ETFs to Watch
- Top Life Science ETFs
- Biggest Pharmaceutical ETFs
- Life Science Outlook
- Biotech Outlook
- Cannabis Outlook
- Pharma Outlook
- Psychedelics Outlook
- All Market Outlook Reports
Cardiol Therapeutics Releases Video on Pharmaceutical CBD Market
Cardiol Therapeutics Inc. (TSX:CRDL) (OTC:CRTPF) has released a video regarding the progress it has made in development of its pharmaceutical-grade CBD compound.
Cardiol Therapeutics Inc. (TSX:CRDL) (OTC:CRTPF) has released a video regarding the progress it has made in development of its pharmaceutical-grade CBD compound. According to President and CEO David Elsley, there are a number of reasons to be excited about the future of Cardiol and the emerging CBD market. “Cannabidiol is in high demand and short supply in many regions of the world. We have a state-of-the-art formulation and a state-of-the-art supply chain capable of meeting that demand with the purest most advanced form of that cannabidiol. We see a significant revenue opportunity because our supply chain is positioned to manufacture one million grams of pure pharmaceutical cannabidiol at the highest level of purity in the industry today.”
Elsley sees the cannabidiol market as a $100 million opportunity based on current CBD price structures. “The average retail price for cannabidiol in a less-pure form than what we’re offering is $100 or more per gram, so it’s a $100 million opportunity and we can supply that opportunity this year,” said Elsley during the video. The company is currently researching the anti-inflammatory effects of cannabidiol on heart patients when the compound is directly delivered to the site of a specific injury.
Watch the full video here.
Click here to connect with Cardiol Therapeutics (TSX:CRDL) for an investor presentation.
Latest News
Cardiol Therapeutics Investor Kit
- Corporate info
- Insights
- Growth strategies
- Upcoming projects
GET YOUR FREE INVESTOR KIT
Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.